Download PDF
Thromb Haemost
DOI: 10.1055/s-0043-1770724
Stroke, Systemic or Venous Thromboembolism

Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis

Yuxiang Zheng    *
1   Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Siyuan Li   *
2   Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
,
Xiao Liu   *
3   Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
,
Gregory Y. H. Lip    **
4   Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
5   Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
,
Linjuan Guo
6   Department of Cardiology, Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang of Jiangxi, China
,
Wengen Zhu
7   Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
› Author Affiliations Funding This study was supported by the National Natural Science Foundation of China (82100273) and Guangdong Natural Science Foundation (2023A1515012798).
› Further Information
Also available at
    Permissions and Reprints


Abstract

Background The aim of the present meta-analysis was to evaluate the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients with polypharmacy.

Methods and Results Randomized controlled trials or observational studies reporting the data of NOACs versus VKAs among AF patients with polypharmacy were included. The search was performed in the PubMed and Embase databases up to November 2022. A total of 12 studies involving 767,544 AF patients were included. For the primary outcomes, the use of NOACs compared with VKAs was significantly associated with a reduced risk of stroke or systemic embolism in AF patients with moderate polypharmacy (hazard ratio [HR]: 0.77 [95% confidence interval [CI]: 0.69–0.86]) and severe polypharmacy (HR: 0.76 [95% CI: 0.69–0.82]), but there was no significant difference in major bleeding (moderate polypharmacy: HR: 0.87 [95% CI: 0.74–1.01]; severe polypharmacy: HR: 0.91 [95% CI: 0.79–1.06]) between the two groups. In secondary outcomes, there were no differences in the rates of ischemic stroke, all-cause death, and gastrointestinal bleeding between the NOAC- and VKA- users, but NOAC users had a reduced risk of any bleeding compared with VKA- users. Compared with VKAs, the risk of intracranial hemorrhage was reduced in NOAC- users with moderate polypharmacy but not severe polypharmacy.

Conclusion In patients with AF and polypharmacy, NOACs showed advantages over VKAs in stroke or systemic embolism and any bleeding, and were comparable to VKAs for major bleeding, ischemic stroke, all-cause death, intracranial hemorrhage, and gastrointestinal bleeding.

Keywords

atrial fibrillation - non-vitamin K antagonist oral anticoagulants - vitamin K antagonists - polypharmacy - meta-analysis

Authors' Contribution

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.


* Co-first authors.


** Senior author.


The review process for this paper was fully handled by Christian Weber, Editor in Chief.


Supplementary Material



Publication History

Received: 28 January 2023

Accepted: 22 May 2023

Article published online:
03 July 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kato ET, Goto S, Giugliano RP. Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev 2019; 49: 115-124
    CrossrefPubMedGoogle Scholar
  • 2 Di Carlo A, Bellino L, Consoli D. et al; National Research Program: Progetto FAI. La Fibrillazione Atriale in Italia. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace 2019; 21 (10) 1468-1475
    CrossrefPubMedGoogle Scholar
  • 3 Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17 (01) 230
    CrossrefPubMedGoogle Scholar
  • 4 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    Google Scholar
  • 5 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 6 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 7 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 8 Eggebrecht L, Nagler M, Göbel S. et al. Relevance of polypharmacy for clinical outcome in patients receiving vitamin K antagonists. J Am Geriatr Soc 2019; 67 (03) 463-470
    CrossrefPubMedGoogle Scholar
  • 9 Jaspers Focks J, Brouwer MA, Wojdyla DM. et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 2016; 353: i2868
    CrossrefPubMedGoogle Scholar
  • 10 Piccini JP, Hellkamp AS, Washam JB. et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation 2016; 133 (04) 352-360
    CrossrefPubMedGoogle Scholar
  • 11 Chao TF, Joung B, Takahashi Y. et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
    CrossrefPubMedGoogle Scholar
  • 13 Fincke BG, Miller DR, Spiro III A. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med 1998; 13 (03) 182-185
    CrossrefPubMedGoogle Scholar
  • 14 By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019; 67 (04) 674-694
    CrossrefPubMedGoogle Scholar
  • 15 Lip GYH, Keshishian A, Kang A. et al. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. Eur Heart J Cardiovasc Pharmacother 2021; 7 (05) 405-414
    CrossrefPubMedGoogle Scholar
  • 16 Harskamp RE, Teichert M, Lucassen WAM, van Weert HCPM, Lopes RD. Impact of polypharmacy and P-glycoprotein- and CYP3A4-modulating drugs on safety and efficacy of oral anticoagulation therapy in patients with atrial fibrillation. Cardiovasc Drugs Ther 2019; 33 (05) 615-623
    CrossrefPubMedGoogle Scholar
  • 17 Feng X, Sambamoorthi U, Innes K. et al. Predictors of major bleeding among working-age adults with atrial fibrillation: evaluating the effects of potential drug-drug interactions and switching from warfarin to non-vitamin K oral anticoagulants. Cardiovasc Drugs Ther 2018; 32 (06) 591-600
    CrossrefPubMedGoogle Scholar
  • 18 Brais C, Larochelle J, Turgeon MH. et al. Predictors of direct oral anticoagulants utilization for thromboembolism prevention in atrial fibrillation. J Pharm Pharm Sci 2017; 20: 8-14
    CrossrefPubMedGoogle Scholar
  • 19 Momo K, Shu-Toh K, Kaneko M. et al. Predictive factors associated with bleeding in atrial fibrillation patients treated with anti-coagulant drugs using a large claims database. PLoS One 2020; 15 (08) e0238233
    CrossrefPubMedGoogle Scholar
  • 20 Admassie E, Chalmers L, Bereznicki LR. Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study. Eur J Clin Pharmacol 2017; 73 (12) 1681-1689
    CrossrefPubMedGoogle Scholar
  • 21 Jang BM, Lee OS, Shin EJ. et al. Factors related to inappropriate edoxaban use. J Clin Pharm Ther 2019; 44 (05) 760-767
    CrossrefPubMedGoogle Scholar
  • 22 Marco Garbayo JL, Koninckx Cañada M, Pérez Castelló I, Faus Soler MT, Perea Ribis M. Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban. Eur J Hosp Pharm Sci Pract 2019; 26 (02) 106-112
    PubMedGoogle Scholar
  • 23 Alberts MJ, He J, Kharat A, Ashton V. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. Am J Cardiovasc Drugs 2022; 22 (04) 425-436
    CrossrefPubMedGoogle Scholar
  • 24 Berger JS, Laliberté F, Kharat A. et al. Comparative effectiveness and safety of rivaroxaban and warfarin among nonvalvular atrial fibrillation (NVAF) patients with obesity and polypharmacy in the United States (US). Adv Ther 2021; 38 (07) 3771-3788
    CrossrefPubMedGoogle Scholar
  • 25 Chen N, Alam AB, Lutsey PL. et al. Polypharmacy, adverse outcomes, and treatment effectiveness in patients ≥75 with atrial fibrillation. J Am Heart Assoc 2020; 9 (11) e015089
    CrossrefPubMedGoogle Scholar
  • 26 Martinez BK, Baker WL, Sood NA. et al. Influence of polypharmacy on the effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation. Pharmacotherapy 2019; 39 (02) 196-203
    CrossrefPubMedGoogle Scholar
  • 27 Mentias A, Heller E, Vaughan Sarrazin M. Comparative effectiveness of rivaroxaban, apixaban, and warfarin in atrial fibrillation patients with polypharmacy. Stroke 2020; 51 (07) 2076-2086
    CrossrefPubMedGoogle Scholar
  • 28 Millenaar D, Schumacher H, Brueckmann M. et al. Cardiovascular outcomes according to polypharmacy and drug adherence in patients with atrial fibrillation on long-term anticoagulation (from the RE-LY trial). Am J Cardiol 2021; 149: 27-35
    CrossrefPubMedGoogle Scholar
  • 29 van den Dries CJ, van Doorn S, Souverein P. et al. The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation. TH Open 2020; 4 (04) e417-e426
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Yamashita T, Akao M, Atarashi H. et al. Effect of polypharmacy on clinical outcomes in elderly patients with non-valvular atrial fibrillation　- a sub-analysis of the ANAFIE registry. Circ J 2022; 87 (01) 6-16
    CrossrefPubMedGoogle Scholar
  • 31 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
    CrossrefPubMedGoogle Scholar
  • 32 Polzin A, Dannenberg L, Wolff G. et al. Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: differences between factor IIa and factor Xa inhibition?. Pharmacol Ther 2019; 195: 1-4
    CrossrefPubMedGoogle Scholar
  • 33 Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?. Ann Pharmacother 2013; 47 (11) 1478-1487
    CrossrefPubMedGoogle Scholar
  • 34 Steffel J, Verhamme P, Potpara TS. et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
    CrossrefPubMedGoogle Scholar
  • 35 Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23 (08) 1296-1310
    CrossrefPubMedGoogle Scholar
  • 36 Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes 2016; 9 (02) 182-185
    CrossrefPubMedGoogle Scholar
  • 37 Komen JJ, Pottegård A, Mantel-Teeuwisse AK. et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace 2021; 23 (11) 1722-1730
    CrossrefPubMedGoogle Scholar